Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

p>

achieved.

Financial Highlights

Net sales of Vancocin(R) were $47.7 million for the fourth quarter of 2007 and $203.8 million for the twelve months of 2007 as compared to $38.5 million and $166.6 million in the respective 2006 periods.

Investment in our product pipeline and the Company continued to grow as research and development (R&D) and marketing, general and administrative (MG&A) expenses were $25.2 million and $72.9 million for the fourth quarter and twelve months of 2007, respectively compared to $10.2 million and $43.7 million for the fourth quarter and twelve months of 2006, respectively. These increases were due primarily to our two phase three studies for Camvia and increased personnel to support our clinical pipeline, along with increased marketing, general and administrative expense due to increases in medical education, share-based compensation and legal and consulting costs.

Operating income in the fourth quarter and twelve months ended December 31, 2007 was $19.0 million and $115.8 million, respectively, compared to $25.1 million and $98.8 million in the fourth quarter and twelve months of 2006, respectively. Operating income in the fourth quarter decreased primarily due to higher R&D and MG&A costs discussed above partially offset by the higher net sales. Operating income for the twelve months of 2007 increased due to higher net sales and lower cost of sales, partially offset by the increase in R&D and MG&A expenses.

"2007 represented a period of strong momentum for ViroPharma - clinical momentum, organizational momentum, and operational momentum - as we continue to be driven by our commitment to bring essential therapies to patients with few, if any, treatment options," commented Michel de Rosen, ViroPharma's chief executive officer. "Our 2007 clinical efforts were primarily driven by Camvia, which was granted Orphan Drug designation in both the U.S. and E.U. and gained global momentum through our pivotal ph
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... (PRWEB) April 20, 2015 Mutare ... has secured nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, ... , Dr. Kosinski brings a unique combination of ... to the Mutare Health team as ... communication, collaboration, and quality of care in the ...
(Date:4/20/2015)... Danbury, Connecticut (PRWEB) April 20, 2015 ... that Moreen Donahue, DNP, RN, NEA-BC, FAAN who ... for Nursing Education and Research in September 2014, ... Chief Nursing Officer to lead the development of ... In this newly created role, Donahue will be ...
(Date:4/20/2015)... April 20, 2015 Novatus, a ... further expanded its service level to the growing ... in Amsterdam and Paris. After a rigorous ... sophisticated levels of resilience, security and operational expertise, ... milestone for Novatus as we expand our footprint ...
(Date:4/20/2015)... Southfield, MI (PRWEB) April 20, 2015 ... products is a personal matter that many customers would prefer ... offering as of March 30th a discreet delivery method allowing ... have them arrive at their home without fear of a ... This discreet shipping method is available now on all orders ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 America’s ... the U.S. health insurance industry, is seeking greater ... the recent controversy involving surgical tools called power ... U.S. Senator Robert Casey (D-PA) dated April 14th, ... uterine morcellation point to “serious gaps in the ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:Novatus Expands into European Data Centers 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4
... years,since the nation,s capital was stunned by terrorist ... are we any better prepared now than we,were ... Hospital,Center will answer the question, Tuesday evening, October ... READY?" -- as they present the,Washington Hospital Center,s ...
... Renowned Therapist Challenges Modern Psychology and Explodes Myths of ,Why ... ... children have a,genetic predisposition to bad behavior and are more difficult to ... parents, has,been the cross parents have had to bear for decades, placing ...
... October 29, 2007 - A new study published in ... self-reported active epilepsy and health-related quality of life among ... data collected in the 2003 California Health Interview Survey ... finds that in 2003, almost 300,000 (1.2 percent) adults ...
... - Monthly blog will appear in conjunction with ... 29 The Kellogg School,of Management at Northwestern ... monthly blog developed by David Dranove, the Kellogg ... Management.,"Code Red" is accessible at the following link:, ...
... (Amex: PRZ ), one of the nation,s leading ... announced that at its,2007 Annual Meeting of Stockholders held ... of board members and the,ratification of Brimmer, Burek & ... ending December 31, 2007. Re-elected board members, who ...
... Pharmaceuticals,Inc., which discovers and develops novel antiviral therapeutics ... of Steven D.,Skolsky as its President and Chief ... of the Board of Directors. "Sequoia is ... as Steven Skolsky," said Chris Mirabelli, Chairman of ...
Cached Medicine News:Health News:Are We Ready? Washington Hospital Center Sets Precedents in Preparedness for 9/11-Style Attacks 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 3Health News:Kellogg School of Management Announces 'Code Red' 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 3Health News:Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer 2
(Date:4/20/2015)... 20, 2015 International Isotopes Inc. (OTCQB: ... shareholders with the following update on its business ... Historically, INIS has produced and sold ... models of sealed sources for medical and industrial ... therapy, security examination, and radiography.  Due to technical ...
(Date:4/20/2015)... KANNAPOLIS, N.C. , April 20, 2015 /PRNewswire/ ... managed care organization that focuses on high-tech, high-touch ... for delivering behavioral health services during the National ... The event, which takes place April 20–22, 2015, ... in Orlando, Fla. , attracts ...
(Date:4/20/2015)... , April 20, 2015 Eli Lilly ... the investigational medicine ixekizumab was statistically superior to placebo ... (PsA), as demonstrated by the proportion of patients achieving ... assessment that represents a 20 percent reduction in disease ... of Rheumatology response criteria. During the 24-week, Phase 3 ...
Breaking Medicine Technology:International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 2International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 3International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 4International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 5Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... LAUSANNE, Switzerland, July 21 Debiopharm Group,(Debiopharm), ... focus on the development of prescription drugs that ... agency for therapeutic products,Swissmedic, has issued a marketing ... prescribed for a reversible reduction,of serum testosterone to ...
... Ueno, Ltd. announced on July 17 that as a phase 1 ... by our company as a therapeutic drug of androgenetic alopecia (male ... , The phase 1 clinical study of ... study and 5-day repeated-dose study. Since no serious adverse event occurred ...
Cached Medicine Technology:Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 3R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: